ANI Pharmaceuticals, Inc. (ANIP) SEC Filings & Earnings Calls

Product Mix Shift to Royalty-Bearing Products

“Cost of sales, as a percentage of net revenues, increased to 37.6% from 35.3% for the three months ended June 30, 2026, compared to the same period in 2025, primarily due to a shift in product mix year over year and an increase in sales of products that bear a royalty payable, and the non-recurrence of prior year sales from Prucalopride.” · word for word

ILUVIEN Revenue Decline

“ILUVIEN net revenues were $18.7 million in the second quarter, down 16% from the prior year period.” · word for word

ILUVIEN revenue decline of 16.1% YoY due to timing of international shipments

“ILUVIEN net revenues were $18.7 million for the second quarter of 2026, a decrease of 16.1% over the same period in 2025 based primarily on timing of international shipments” · word for word

Brands revenue decline of 10.5% YoY due to normalization in demand

“Brands net revenues were $11.8 million for the second quarter of 2026, a decrease of 10.5% over the same period in 2025, reflecting a normalization in demand for certain products” · word for word

Product Mix Shift to Royalty-Bearing Products

“Cost of sales, as a percentage of net revenues, increased to 39.4% from 37.1% ... primarily due to a shift in product mix year over year and an increase in sales of products that bear a royalty payable” · word for word

Brands Portfolio Demand Decline

“Net revenues for Brands portfolio of pharmaceutical products were $12.3 million ... a decrease of $12.8 million compared to $25.1 million for the same period in 2025, driven by a net decrease in demand for certain products” · word for word

Supplier Concentration

“During the three months ended March 31, 2026, approximately 33% of our raw material inventory purchases were from one domestic supplier.” · word for word

Seasonality and insurance re-verification delays could impact Cortrophin Gel revenue timing.

“First quarter of 2026 reflected seasonality related primarily to the impact of insurance re-verifications; re-verifications took slightly longer to clear due to increased patient volume and weather-related office closures.” · word for word

ILUVIEN franchise reset year

“Within ophthalmology, 2025 was a reset year for ILUVIEN.” · word for word

Dependence on Cortrophin Gel for growth

“Cortrophin Gel represents 82% of Rare Disease revenue and 39% of total revenue.”

Change in auditor may indicate accounting or governance concerns, but no details provided.

“Item 4.01: changed its independent registered accounting firm.”

Single-source API dependency

“During the year ended December 31, 2025, approximately 17%, of our raw materials and API purchases were from one domestic supplier.” · word for word

Medicaid rebate accrual uncertainty

“Our Medicaid rebate accruals have increased and continue to increase due to our acquisitions.” · word for word

Commercialization risk for Cortrophin Gel and ILUVIEN

“Our approved products, including Cortrophin Gel and ILUVIEN, may not achieve commercialization at levels of market acceptance.” · word for word

ILUVIEN revenue declined 28.2% YoY in Q4, indicating potential competitive or market headwinds.

“ILUVIEN net revenues decreased 28.2% year-over-year in Q4 2025.”

Brands segment revenue declined 37.9% YoY in Q4, reflecting normalization of demand.

“Brands net revenues decreased 37.9% year-over-year in Q4 2025.”

Supply chain and regulatory risks for key products

“Reliance on single source third party contract manufacturing for Cortrophin Gel and ILUVIEN.” · word for word

Leadership transition risk is low given orderly process and no disagreement.

“No disagreement cited; outgoing chairman remains until annual meeting.”

Forward-looking statements include risks related to tariffs, supply chain, and regulatory changes.

“Risks include increased costs due to tariffs, supply chain disruptions, and regulatory approvals.”

Generic Competition Pressure

“We currently anticipate that revenues from Generic pharmaceutical products will be lower in the fourth quarter compared to that in the third quarter of 2025 due to expected competition on certain products.” · word for word

Supplier Concentration

“During the three months ended September 30, 2025, approximately 21% of our raw material inventory purchases were from one domestic supplier.” · word for word

ILUVIEN revenue pressure from Medicare access and YUTIQ transition

“ILUVIEN net revenues pressured due to continued reduced access for Medicare patients and utilization of remaining YUTIQ units.”

Product mix impact on non-GAAP gross margin

“Non-GAAP gross margin decreased from 59.9% to 59.2% due to product mix, including lower margins on partnered generic product.”